首页 > 最新文献

Kaku igaku. The Japanese journal of nuclear medicine最新文献

英文 中文
[A Report on Health Resource Use of Internal Radiation Therapy with 131I-MIBG (2nd Survey)]. 131I-MIBG内放射治疗卫生资源利用报告(第二次调查)。
Kaku igaku. The Japanese journal of nuclear medicine
Pub Date : 2023-01-01 DOI: 10.18893/kakuigaku.tr.2301
Katsuhiko Kato, Soichi Nakamura, Hiroyasu Sugano, Seigo Kinuya

Internal radiation therapy using Iodine-131 metaiodobenzylguanidine (131I-MIBG) for neuroblastoma has been discussed whether a special application scheme for off-labeled drugs called "Kouchi-Shinsei" could be applied to neuroblastoma or not by the Evaluation Committee on Unapproved or Off-labeled Drug with High Medical Needs (the Committee); if the Committee determines that Kouchi-Shinsei is applicable, neuroblastoma indication is expected to be regulatory approved within a year. Since a NHI medical technical fee is not yet set for neuroblastoma, the Japanese Society of Nuclear Medicine surveyed health resource use via a questionnaire survey of medical institution that has conducted a Japanese Advanced Medical Care B clinical study in neuroblastoma. Results showed that the necessary total cost per patient is 1,847,451 JPY when calculated based on the Draft Proposal for Medical Examination Value (Ver. 7.3) of the Japanese Health Insurance Federation for Surgery. Because follow-up is necessary for 3 months after administration, it was considered that an appropriate fee per patient is 1,847,451 JPY and an appropriate NHI medical technical fee per patient is 46,186 points which can be claimed up to once a month for 4 times including the initial month of the treatment.

高医疗需求未批准或超说明书药品评价委员会(委员会)讨论了神经母细胞瘤内放疗使用碘-131间甲基多苄基胍(131I-MIBG)治疗超说明书药品的特殊申请方案“Kouchi-Shinsei”是否可以应用于神经母细胞瘤;如果委员会确定Kouchi-Shinsei适用，神经母细胞瘤适应症有望在一年内获得监管批准。由于国民健康保险(NHI)对神经母细胞瘤的医疗技术费用尚未确定，日本核医学学会(Japanese Society of Nuclear Medicine)通过对开展日本先进医疗保健B临床研究的医疗机构进行问卷调查，调查了卫生资源的使用情况。结果表明，根据日本外科健康保险联合会的《医疗检查价值提案草案》(第7.3版)计算，每位患者的必要总费用为1 847 451日元。由于在给药后需要随访3个月，因此认为每位患者适当的费用为1,847,451日元，每位患者适当的国民健康保险医疗技术费用为46,186点，每月最多可申领一次，共4次，包括治疗的第一个月。
{"title":"[A Report on Health Resource Use of Internal Radiation Therapy with <sup>131</sup>I-MIBG (2<sup>nd</sup> Survey)].","authors":"Katsuhiko Kato,&nbsp;Soichi Nakamura,&nbsp;Hiroyasu Sugano,&nbsp;Seigo Kinuya","doi":"10.18893/kakuigaku.tr.2301","DOIUrl":"https://doi.org/10.18893/kakuigaku.tr.2301","url":null,"abstract":"<p><p>Internal radiation therapy using Iodine-131 metaiodobenzylguanidine (<sup>131</sup>I-MIBG) for neuroblastoma has been discussed whether a special application scheme for off-labeled drugs called \"Kouchi-Shinsei\" could be applied to neuroblastoma or not by the Evaluation Committee on Unapproved or Off-labeled Drug with High Medical Needs (the Committee); if the Committee determines that Kouchi-Shinsei is applicable, neuroblastoma indication is expected to be regulatory approved within a year. Since a NHI medical technical fee is not yet set for neuroblastoma, the Japanese Society of Nuclear Medicine surveyed health resource use via a questionnaire survey of medical institution that has conducted a Japanese Advanced Medical Care B clinical study in neuroblastoma. Results showed that the necessary total cost per patient is 1,847,451 JPY when calculated based on the Draft Proposal for Medical Examination Value (Ver. 7.3) of the Japanese Health Insurance Federation for Surgery. Because follow-up is necessary for 3 months after administration, it was considered that an appropriate fee per patient is 1,847,451 JPY and an appropriate NHI medical technical fee per patient is 46,186 points which can be claimed up to once a month for 4 times including the initial month of the treatment.</p>","PeriodicalId":17738,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10829217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Kaku igaku. The Japanese journal of nuclear medicine
Pub Date : 2023-01-01 DOI: 10.18893/kakuigaku.arm.2335
{"title":"","authors":"","doi":"10.18893/kakuigaku.arm.2335","DOIUrl":"https://doi.org/10.18893/kakuigaku.arm.2335","url":null,"abstract":"","PeriodicalId":17738,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9973028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Kaku igaku. The Japanese journal of nuclear medicine
Pub Date : 2023-01-01 DOI: 10.18893/kakuigaku.arm.2334
{"title":"","authors":"","doi":"10.18893/kakuigaku.arm.2334","DOIUrl":"https://doi.org/10.18893/kakuigaku.arm.2334","url":null,"abstract":"","PeriodicalId":17738,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9975681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[The 44th Report on Survey of the Adverse Reaction to Radiopharmaceuticals (The 47th Survey in 2021)]. [第44次放射性药品不良反应调查报告(2021年第47次调查)]。
Kaku igaku. The Japanese journal of nuclear medicine
Pub Date : 2023-01-01 DOI: 10.18893/kakuigaku.rp.2331
Hidehiko Okazawa, Tomoya Uehara, Ichiei Kuji, Tatsuya Higashi, Mana Yoshimura

This survey was performed in order to investigate the incidence of adverse reactions to radiopharmaceuticals in FY2021 in Japan. It was based on responses to questionnaires sent to nuclear medicine institutions. Replies were obtained from 970 institutions out of 1,194 to which the questionnaire had been sent. A total of 928,921 radiopharmaceutical administrations were reported. Twelve cases of adverse reactions were reported. The incidence of adverse reactions per 100,000 cases was 1.3. Three cases of defective products were reported. The incidence of defective products per 100,000 cases was 0.3.

本调查是为了调查日本2021财年放射性药物不良反应的发生率。该报告是根据对核医学机构的问卷调查得出的。在收到调查表的1 194个机构中，收到了970个机构的答复。共报告了928,921起放射性药物管理事件。报告不良反应12例。不良反应发生率为每10万例1.3例。报告了三例次品。每10万例不良品发生率为0.3。
{"title":"[The 44th Report on Survey of the Adverse Reaction to Radiopharmaceuticals (The 47th Survey in 2021)].","authors":"Hidehiko Okazawa,&nbsp;Tomoya Uehara,&nbsp;Ichiei Kuji,&nbsp;Tatsuya Higashi,&nbsp;Mana Yoshimura","doi":"10.18893/kakuigaku.rp.2331","DOIUrl":"https://doi.org/10.18893/kakuigaku.rp.2331","url":null,"abstract":"<p><p>This survey was performed in order to investigate the incidence of adverse reactions to radiopharmaceuticals in FY2021 in Japan. It was based on responses to questionnaires sent to nuclear medicine institutions. Replies were obtained from 970 institutions out of 1,194 to which the questionnaire had been sent. A total of 928,921 radiopharmaceutical administrations were reported. Twelve cases of adverse reactions were reported. The incidence of adverse reactions per 100,000 cases was 1.3. Three cases of defective products were reported. The incidence of defective products per 100,000 cases was 0.3.</p>","PeriodicalId":17738,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10727475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Kaku igaku. The Japanese journal of nuclear medicine
Pub Date : 2023-01-01 DOI: 10.18893/kakuigaku.arm.2333
{"title":"","authors":"","doi":"10.18893/kakuigaku.arm.2333","DOIUrl":"https://doi.org/10.18893/kakuigaku.arm.2333","url":null,"abstract":"","PeriodicalId":17738,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9666407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Kaku igaku. The Japanese journal of nuclear medicine
Pub Date : 2023-01-01 DOI: 10.18893/kakuigaku.arm.2332
{"title":"","authors":"","doi":"10.18893/kakuigaku.arm.2332","DOIUrl":"https://doi.org/10.18893/kakuigaku.arm.2332","url":null,"abstract":"","PeriodicalId":17738,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9145787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[The 43rd Report on the Survey of Adverse Reactions to Radiopharmaceuticals (46th Survey in 2020)]. [第43次放射性药品不良反应调查报告(2020年第46次调查)]。
Kaku igaku. The Japanese journal of nuclear medicine
Pub Date : 2022-01-01 DOI: 10.18893/kakuigaku.rp.2231
Hidehiko Okazawa, Tomoya Uehara, Ichiei Kuji, Tatsuya Higashi, Mana Yoshimura

This survey was performed to investigate the incidence of adverse reactions to radiopharmaceuticals in FY2020 in Japan. The results are based on responses to questionnaires sent to nuclear medicine centers. Replies were obtained from 1,006 centers out of 1,212 to which the questionnaire was sent. A total of 940,758 administrations of radiopharmaceuticals were reported. There were 17 cases with adverse reactions, giving an incidence of adverse reactions of 1.8 per 100,000 cases. Two cases of defective products were reported, giving an incidence of defective products of 0.2 per 100,000 cases.

本调查旨在调查2020财年日本放射性药物不良反应的发生率。这些结果是基于对核医学中心的问卷调查。在收到问卷的1,212个中心中，有1,006个中心给出了答复。共报告了940,758次放射性药物用药。不良反应17例，不良反应发生率为1.8 / 10万例。报告了两例次品，次品发生率为每10万例0.2例。
{"title":"[The 43rd Report on the Survey of Adverse Reactions to Radiopharmaceuticals (46th Survey in 2020)].","authors":"Hidehiko Okazawa,&nbsp;Tomoya Uehara,&nbsp;Ichiei Kuji,&nbsp;Tatsuya Higashi,&nbsp;Mana Yoshimura","doi":"10.18893/kakuigaku.rp.2231","DOIUrl":"https://doi.org/10.18893/kakuigaku.rp.2231","url":null,"abstract":"<p><p>This survey was performed to investigate the incidence of adverse reactions to radiopharmaceuticals in FY2020 in Japan. The results are based on responses to questionnaires sent to nuclear medicine centers. Replies were obtained from 1,006 centers out of 1,212 to which the questionnaire was sent. A total of 940,758 administrations of radiopharmaceuticals were reported. There were 17 cases with adverse reactions, giving an incidence of adverse reactions of 1.8 per 100,000 cases. Two cases of defective products were reported, giving an incidence of defective products of 0.2 per 100,000 cases.</p>","PeriodicalId":17738,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40317988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Kaku igaku. The Japanese journal of nuclear medicine
Pub Date : 2022-01-01 DOI: 10.18893/kakuigaku.arm.2236
{"title":"","authors":"","doi":"10.18893/kakuigaku.arm.2236","DOIUrl":"https://doi.org/10.18893/kakuigaku.arm.2236","url":null,"abstract":"","PeriodicalId":17738,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40636135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Kaku igaku. The Japanese journal of nuclear medicine
Pub Date : 2022-01-01 DOI: 10.18893/kakuigaku.abm.2237
{"title":"","authors":"","doi":"10.18893/kakuigaku.abm.2237","DOIUrl":"https://doi.org/10.18893/kakuigaku.abm.2237","url":null,"abstract":"","PeriodicalId":17738,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40636136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Joint Program]. (联合项目)。
Kaku igaku. The Japanese journal of nuclear medicine
Pub Date : 2022-01-01 DOI: 10.18893/kakuigaku.59.S375
{"title":"[Joint Program].","authors":"","doi":"10.18893/kakuigaku.59.S375","DOIUrl":"https://doi.org/10.18893/kakuigaku.59.S375","url":null,"abstract":"","PeriodicalId":17738,"journal":{"name":"Kaku igaku. The Japanese journal of nuclear medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79919601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
Kaku igaku. The Japanese journal of nuclear medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1